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NEUROPLASTICITY HYPOTHESIS OF THE MECHANISM OF 
ELECTROCONVULSIVE THERAPY: A PROTON MAGNETIC RESONANCE 
AND FUNCTIONAL CONNECTIVITY INVESTIGATION 
TIAN YUE SONG 
 
ABSTRACT 
Introduction: Major depressive disorder (MDD) is characterized by ongoing 
feelings of guilt, sadness, and memory and cognition impairment. It is a 
multidimensional illness that affects many functionally integrated pathways of the 
brain. Understanding the underlying brain dysfunction that gives rise to this 
complex illness has been challenging, and by extension the search for 
appropriate treatments. MDD patients who are considered treatment resistant 
make up the primary population that receives electroconvulsive therapy (ECT). 
Remarkably, ECT shows a 75% remission rate in this patient population and is 
considered the “gold standard” treatment for major depression. Although the 
exact mechanism of its function is unknown, it is well accepted that the induced 
grand-mal seizure confers its therapeutic effect. The seizure likely has broad 
effect that somehow corrects the underlying dysfunction in brain circuitry. Here, 
we specifically examined studies of functional connectivity and metabolite 
changes.  
Methods: Through literature search, we examined six studies in functional 
connectivity and four studies in magnetic resonance spectroscopy (MRS).  
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Results:  
Functional Connectivity: Studies have found that after bilateral ECT treatments, 
patients with major depression showed reduction of functional connectivity (FC) 
from the left dorsolateral prefrontal cortex (DLPFC) to other cortical and limbic 
structures. Correlated activity between the superior frontal gyri, middle frontal gyri 
and angular gyri were significantly increased after ECT. Hyperdeactivation of the 
orbitofrontal cortex to negative emotional stimuli in patients was decreased, and 
it was associated with improvement in depressive symptoms. Regional activity in 
the subgenual anterior cingulate cortex (sgACC) and functional connectivity 
between the sgACC and left hippocampus in treatment naïve patients after ECT 
were increased and correlated to reduction of depressive symptoms. Reduced 
connectivity between the amygdala and sgACC and increased connectivity 
between the amygdala and DLPFC were found by sequential assessments over 
a course of ECT treatments. Lastly, ECT increased the functional connectivity 
between DLPFC and the default mode network.  
MRS: Studies found decreased levels of glutamate or combined 
glutamate/glutamine/ GABA levels in patients in the anterior cingulate cortex and 
dorsolateral prefrontal cortex compared to healthy controls. Additionally, it was 
found that glx levels increased after ECT treatments and that this increase was 
only in those who responded to treatment. Lastly, GABA level increased after 
ECT treatment in the occipital cortex. 
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Discussion: Results from functional connectivity and brain metabolite studies in 
patients with major depression point to induced neuroplasticity as part of ECT’s 
therapeutic mechanism. Remodeling connectivity and mediating metabolite 
changes both will require modifications at the synaptic level. The wide spread 
changes seen in several different brain regions that have been implicated in 
depression further suggests that ECT’s effects are both highly specific and  
broad. 
Conclusion: Electroconvulsive therapy has consistently demonstrated impressive 
efficacy among the most severely depressed patients and is known to produce 
widely distributed effects in the brain. However, this also makes assessing its 
therapeutic mechanism challenging. Magnetic resonance imaging studies 
assessing functional connectivity and brain metabolite levels have demonstrated 
that ECT likely produces neuroplastic changes to remodel aberrant connectivity 
and dysfunctional excitatory and inhibitory neurotransmission in cortical and 
limbic areas. Although these findings should be interpreted with caution, this field 
of research has provided an unprecedented opportunity to examine the living 
brain in great detail. Further studies with larger sample sizes and improved 
technical specifications will likely yield greater results.  
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INTRODUCTION AND BACKGROUND 
 
History of Electroconvulsive Therapy 
In 1934, Ladislas Meduna, a Hungarian neuropsychiatrist, injected an extract 
of camphor into a patient who was considered hopeless for his catatonic 
schizophrenia (Fink, 2001). Forty five minutes after the injection, the patient lost 
consciousness and underwent a brief grand-mal seizure but survived the ordeal. 
Meduna continued camphor injections four more times, two days after the last 
convulsion, the patient came out of his catatonic state and was even able to 
engage in conversation. Unfortunately, this positive effect was short-lived and the 
patient rapidly relapsed back to a catatonic state. However, Meduna did not give 
up and continued treatments with camphor. He noted that with each successive 
treatment, the patient remitted for longer periods of time. Eventually, the patient 
was able to resume work and normal daily activities. The idea of inducing a 
grand-mal seizure as treatment for psychiatric conditions came from Meduna’s 
earlier work studying glial cells. In his postmortem examinations, he noted that 
the glial cell concentration was much higher for patients who had an epileptic 
disorder than those who had dementia. Additionally, patients who suffered from 
dementia experienced improvements in their symptom when they developed a 
seizure disorder. Meduna suspected that the seizures helped to increase the 
amount of glial cells in these patients and helped relieved their symptoms and 
thought that perhaps it is also helpful in schizophrenia (Fink, 2014b). Meduna 
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went on to treat five more patients with schizophrenia and saw improvements in 
all (Fink, 2001), and is regarded as the father of convulsive therapy (Bolwig, 
2014).  
 Although camphor and Metrazol, alternative convulsive agents, were 
successful in inducing seizures, their reliability was low. There was a significant 
delay in the induced seizure with camphor injection and Metrazol frequently 
required multiple injections to achieve a seizure, physicians quickly looked for 
more reliable ways to induce convulsions (Fink, 2001). In 1938, two Italian 
physicians, Cerletti and Bini, successfully induced an immediate seizure using 
electricity by placing electrodes on the temples of a patient. By the 1950s, 
electroconvulsive therapy (ECT) became a principal treatment for a broad range 
of psychiatric illnesses (Fink, 2014; Hirshbein and Sarvananda, 2008). Although 
the specific mechanism for ECT was unknown, the general belief for its treatment 
effect was that “convulsions disrupted problems in the patient’s thinking and 
restored some semblance of normality” (Hirschbein and Sarvananda, 2008). 
Therefore, the therapeutic effect of ECT is largely dependent on the induction of 
a grand-mal seizure (Fink, 2001). This view is backed up by studies of 
incomplete seizures, where the treatments were mostly ineffective (Fink, 2001). 
As such, the induction of adequate seizures is guided by measurements of a 
seizure threshold (ST). ST is the lowest stimulation needed to induce an 
adequate seizure (Fink, 2008). It can be measured by two ways, a dose titration 
(DT) method or a half-age method (HA) (Petrides et al., 2009). The DT method 
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starts stimulation at a level anticipated to be below the threshold for a seizure, 
and stimulation is increased at fixed increments (25 or 50mC) until a seizure is 
induced. The HA method estimates the ST by using half of the anticipated 
“percent of charge” given the patient’s age as a starting point (Petrides et al., 
2009).  
Unfortunately, early unmodified administrations of ECT lacked 
standardization, was minimally supported by scientific research and came with 
many side effects (Hirschbein and Sarvananda, 2008). In particular, the 
convulsions frequently produced fractures and dislocations (Gallegos et al., 
2012), hemodynamic complications and inadequate respiration. Consequently, 
patients were often physically restrained during treatment to prevent physical 
harm (Gallegos et al., 2012; Hirshbein, 2008), which induced a great deal of 
anxiety and fear. Patient reports at the time showed a 50% - 80% fear and 
anxiety rate prior to treatment (Gallegos et al., 2012). Although some physicians 
have thought of unmodified treatment as inhumane and degrading (Gallegos et 
al., 2012), ECT‘s side effects were generally accepted and thought of as 
“unavoidable consequences of the larger fight” (Gallegos et al., 2012).  
 Modified ECT was introduced in the 1950s, as a way to reduce patient 
discomfort and improve safety (Gallegos et al., 2008). Sedatives, muscle 
relaxants and ventilation were given prior to treatment to replace physical 
restraints and improve on the cognitive side effects of post-ECT delirium, 
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confusion and agitation seen with unmodified ECT (Gallegos et al., 2008). 
However, the public perception of ECT began to shift in the 1970s, from 
amazement with this highly effective treatment to concerns with its wide spread 
use as a “magic formula that will catapult the unhappy into sudden happiness” 
(Hirshbein and Sarvananda, 2008) and fear based on outdated, unmodified 
images of ECT. These fears were exacerbated by news articles at the time that 
described ECT as a “violent means by which psychiatrists assumed control over 
their patients” and comparing ECT to the electric chair and lobotomy procedures 
(Hirshbein and Sarvananda, 2008).  The dramatic illustration of ECT in the 1975 
film, One Flew Over the Cuckoo’s Nest, further solidified the horrifying image of 
ECT in the public’s mind (Hirschbein and Sarvananda, 2008). Many believed that 
ECT caused irreversible brain damage and altered one’s personality and 
character (Gallegos et al., 2012).  
 By the middle of the 1980s, proponents of ECT began making more 
assertive efforts to inform the public of ECT treatment standards in the modern 
day (Hirshbein and Sarvananda, 2008). Notably, Drs. Max Fink and Harold 
Sackheim pushed for greater scientific research on the use of ECT, its efficacy 
and mechanism (Fink, 1978). They produced numerous evidence based 
publications that both acknowledged the abuse of ECT in history and its 
progressive present day modifications that treat specific illnesses with minimal 
dosing (Hirschbein and Sarvananda, 2008). Thus, early research on ECT has 
focused on understanding and improving its side effects.  
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 One major concern for the use of ECT is induced brain damage through 
electrical stimulation (Fink, 2001). This fear largely stems from postmortem 
studies from the 1940 and 1950s of patients who died from complications of 
unmodified ECT (Devanand et al., 1994). These studies found either no 
pathological change in the gross or micro-structure of the brain to severe 
changes in both (Devanand et al., 1994). However, these studies were poorly 
controlled as cerebrovascular damage can be caused by preexisting conditions 
that are unrelated to ECT. Present day imaging studies, ranging from 
computerized tomography (CT) to magnetic resonance imaging (MRI) have not 
been able to identify consistent brain structural abnormalities in either single ECT 
treatment or a course of ECT (Fink, 2001; Devanand et al., 1994). It is 
noteworthy that early unmodified ECT without adequate ventilation caused 
cognitive defects in some patients, but it is difficult to directly attribute these 
defects to ECT alone (Fink, 2001).  
 Secondary to electrical stimulation, induced grand-mal seizure that is 
central to the therapeutic effect of ECT has also raised concern for brain 
damage. Studies in patients with severe epilepsy have found that they “had a 
lower cell density than comparison subjects, while patients with infrequent and 
moderately frequent seizures had neuron cell densities within the normal range” 
(Devanand et al., 1994). Aggregate results from epilepsy studies in animals and 
humans showed that “neuronal loss occurs only after dozens of closely spaced 
unmodified convulsions or only after several hours of continuous seizure activity 
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if adequate ventilation and muscle relaxation are employed” (Devanand et al., 
1994). However, the seizures elicited during modern day modified ECT are far 
from these requirements, as they typically only last a few seconds and are 
modified with adequate ventilation and muscle relaxants (Devanand et al., 1994).  
 A consistent patient reported side effect of ECT is memory impairment, 
either in events that occurred prior to treatment or difficulty remembering events 
immediately post treatment (Fraser et al., 2008). Approximately 29% - 55% of 
ECT patients report memory loss, but subjective memory impairment reports are 
found to be longer than those reported with objective measures (Fraser et al., 
2008). Memories around the time of ECT treatment are reported as especially 
poor. However, studies have found that patient memory impairments are usually 
only reported at short term follow up, while long term follow ups at 2 months have 
reported no difference in memory ability (Lisanby et al., 2000; Sackeim et al., 
2000). Some studies have even found an improvement in memory at 1 and 6 
months follow up after ECT (Calev et al., 1991). The improvement in memory is 
thought to be a related to post treatment improvement of depressive symptoms 
(Fraser et al., 2008). The difference in subjective and objective memory reports 
and symptom improvement may contribute to the different findings of these 
studies. However, they all suggest that memory impairment in ECT is unlikely 
irreversible.  
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 Research to reduce memory impairment in ECT has focused on the 
impact of different ECT administration on memory performance. As such, 
bilateral (BL) electrode placement was found to produce more severe acute 
memory disruptions than right unilateral placement (RUL) (Sackeim, 2007; 
Weiner, 1986). Patients who received bilateral treatment typically perform worse 
on word recall tasks and event recall tasks. Additionally, traditional sine wave 
form was also found to produce greater cognitive impairment than brief pulse 
square wave (Sackeim et al., 2007; Weiner, 1986). Cognitive advantage of right 
unilateral electrode placement is thought to avoid direct electrical stimulation over 
the dominant left hemisphere (Fink, 2001). Likewise, bilateral electrode 
placement is typically placed over the frontal region of the brain, to directly 
stimulate the motor strip and avoid stimulation to memory centers to minimize 
disruptions of memory (Fink, 2001). However, despite these efforts to improve 
the side effect profile of ECT, research results on the efficacy of RUL are mixed. 
Most studies have found that BL treatments showed more rapid symptom 
improvement with fewer treatments (Abrahams et al., 1991; Kellner et al., 2010; 
Halliday et al., 1968); while other researchers have argued for more prevalent 
use of RUL as first-line treatment given its more favorable side effect profile 
compared to BL treatments (Sackheim et al., 2007). Both approaches aim to 
decrease patient suffering, either by shortening treatment duration or minimizing 
side effects.  
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A more recent modification to ECT is the introduction of ultra-brief pulse 
(UBP) width at 0.3 ms compared to brief pulse (BP) stimulation (0.5-1.5 ms) (Loo 
et al., 2012).  Studies have found that BP stimulation exceeds the ideal pulse 
width to depolarize neurons, which is around 0.1-0.2ms (Loo et al., 2012; Tor et 
al., 2015). By further reducing pulse width to <0.5ms, neurons are more 
efficiently depolarized and “a narrower band of tissue is stimulated and areas 
such as the hippocampus and other temporal lobe structures may be relatively 
spared” (Galvez, 2015; Loo et al., 2012). This is supported by evidence from 
seizure threshold data that showed a lower ST in UBP ECT compared to BP ECT 
(Galvez et al., 2015). However, research on the efficacy and proposed side effect 
improvement of UBP ECT remains controversial and difficult to interpret (Spaans 
et al., 2013). Research efforts on electrode placement, pulse width and wave 
form in ECT practice further align convulsive treatments with modern day 
evidence based practices that seek to minimize harm and discomfort to patients, 
a drastic change from the early days of unmodified ECT.  
 As a result of the misunderstanding of ECT due to its early unmodified 
administration and negative media depiction in the 1970s, the use of ECT was 
largely restricted from, or even rejected by, patients who might have otherwise 
benefitted greatly. For the most part, ECT is given to patients who are severely ill 
or who are considered treatment resistant (failure to respond to at least two 
adequate trials of treatments (Rush et al., 2003)). Despite this limitation, ECT has 
consistently demonstrated impressive efficacy, especially in the treatment of 
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major depressive disorder (MDD), with a 75% remission rate (Husain et al., 2004; 
Hermann, 1995; Weiner, 2001). Additionally, in comparison studies of ECT, 
simulated ECT, and antidepressants (Tricyclic antidepressants, monoamine 
oxidase inhibitors, etc.), it was shown that ECT is significantly more effective than 
all comparison treatments (Pagnin et al., 2004). Today, ECT is considered the 
gold-standard treatment for depression (Spaans et al., 2013).  
Major Depressive Disorder  
 Major depressive Disorder (MDD) is a debilitating psychiatric disorder with 
a ~14% - 16% lifetime prevalence in adults in the United and considered as a 
disease with one of the longest years lived with disability (YLDs) globally (Hasin 
et al., 2005; Kessler et al., 2003, Murray et al., 2013).  By 2020, it will be the 
second leading cause of disability according to the World Health Organization 
(Blazer et al., 2000). Patients who suffer from MDD also show a high co-
morbidity with other mental disorders such as disorders of substance use with 
alcohol and drugs (Hasin et al., 2005; Kessler et al., 2003) and anxiety disorders 
such as panic disorder, posttraumatic stress disorder, and obsessive compulsive 
disorder (Drevets et al., 2008). Additionally, major depression is associated with 
significant cognitive impairment in memory and attention (Kessler et al., 2003; 
Mayberg et al., 1999). Adult patients report an average 35 days of inability to 
carry out their normal activities such as work and social interactions (Kessler et 
al., 2003). They experience depressed mood, fatigue, high anxiety, and/or 
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recurrent thoughts of death and suicide (Anacker et al., 2011), causing severe 
disruptions in personal relationships and economic productivity (Mayberg et al., 
1999; Kessler et al., 2003; Bremner et al., 2002). Combined with MDD’s high 
prevalence, finding effective treatment to alleviate this health issue is extremely 
valuable. 
 The heterogeneity of symptoms of MDD suggests that it is a disease that 
involves multiple neurological mechanisms. One area of research has looked at 
the significant correlation between dysfunction of the hypothalamic-pituitary axis 
(HPA) and symptoms of depression (Anacker et al., 2011). Depression has been 
found to be vulnerable to stress, which perturbs normal HPA function (Luscher et 
al., 2011). HPA hyperactivity has been consistently demonstrated across multiple 
studies of depression, which leads to increased levels of cortisol regulating 
neuronal survival (Anacker et al., 2011; Pariante et al., 2009). It exerts neuronal 
excitability, neurogenesis and memory acquisition by binding to specific 
glucocorticoid receptors (GR) in the brain and regulating the expression of 
neutrophic factors such as brain derived neurotrophic factors (BDNF). These 
neutrophic factors have significant effects on the regulation of neuronal death 
and neurogenesis, especially in the hippocampus (Anacker et al., 2011). 
Therefore, it is hypothesized that hyperactivity of the HPA leading to abnormal 
rises in cortisol levels and dysfunctional GR can both contribute to functional and 
structural changes in the depressed brain (Sousa et al., 2008).   
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Studies have also shown that cortisol induces a marked increase in 
extracellular glutamate levels in the hippocampus, amygdala, and prefrontal 
cortex (PFC) (Sanacora, 2012). Glutamate is the major excitatory 
neurotransmitter in the brain, accounting for 85% of all synapses in the brain 
(Sanacora et al., 2012; Krystal et al., 2002). Cognition and emotion are largely 
mediated by the glutamatergic system, and it is widely accepted that memory 
encoding is due to glutamatergic synaptic plasticity (Sanacora et al., 2012). 
Structural and functional studies of patients with unipolar depression have 
reductions in glial and neuronal cell numbers in cortical and subcortical 
structures, which is correlated to glutamatergic abnormalities (Krystal et al., 
2002). Glia is especially important in the normal functionality of the glutamatergic 
system. Disruption in glia, which contains transporters that remove glutamate 
from synapses, can cause toxic glutamate accumulation and prolong excitatory 
activation (Krystal et al., 2002; Choudary et al., 2005) and ultimately alter 
synaptic transmission (Sanacora et al., 2012). Additionally, glia also stimulates 
release of an N-methyl-D-aspartate receptor (NMDA) receptor coagonist. Loss of 
glia can lead to reductions in NMDA receptor function. Last but not least, glial 
function is also important in providing neuronal energy substrate. The 
combination of increased excitatory input from glutamate accumulation at the 
synapse and decrease in energy supply can cause neuronal atrophy and 
cytotoxic damage (Krystal et al., 2002; Choudary et al., 2005). In MDD, 
glutamate dysfunction is also associated with “maladaptive” neuroplastic 
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changes in excitatory signaling in response to emotional and environmental 
stressors (Sanacora et al., 2012). Glutamate metabolite levels has been found to 
be decreased in the frontal and cingulate cortex but increased in occipital and 
parietal regions in MDD (Sanacora et al., 2012; Sequeira et al., 2009; Auer et al., 
2000). Similarly, gamma-Aminobutyric acid (GABA), the major inhibitory 
neurotransmitter of the brain, used by approximately 40% of all neurons, has also 
been implicated in mood disorders as it is closely related to glutamate 
metabolism (Sanacora et al., 2012; Krystal et al., 2002; Torrey et al., 2005). 
GABA is formed by glutamic acid decarboxylase (GAD) in GABAergic synaptic 
terminals using glutamate as precursor (Brambilla et al., 2003). Main effect of 
GABA is to “balance and fine tune excitatory neurotransmission… including 
monaminergic and cholinergic projections to the forebrain” (Luscher et al., 2011).  
In MDD, GABA has been found to be significantly reduced in occipital cortex, 
anterior cingulate cortex (ACC), dorsomedial/ dorsolaterla PFC (Luscher et al., 
2011). Given the significant alterations seen in the major excitatory and inhibitory 
neurotransmitter systems of the brain, the effects of antidepressant treatments 
on these systems cannot be overlooked.   
 Following the neurotoxic hypothesis, studies have looked specifically at 
alterations in brain volume in MDD. Several studies reported that compared to 
healthy controls, patients show decrease in medial orbitofrontal cortical volume 
(Bremner et al., 2002), decreased ACC volume (Drevets et al., 2008), 
significantly smaller left and right hippocampal volumes correlated to duration of 
 13 
 
major depression (Sheline et al., 1996), and significantly smaller left hippocampal 
volume (Bremner et al., 2000). These studies indicated the neurotoxic role of 
increased cortisol levels as a possible mechanism in the neuronal loss seen in 
MDD patients as similar neuronal loss specifically in the hippocampus has also 
been reported in patients with Cushing’s syndrome (malignant elevated cortisol 
levels) (Bremner et al., 2000; Sheline et al.,1996). The hippocampus is the major 
brain center for memory (Squire et al., 1992), while prefrontal cortices are 
involved in emotional and visceral regulation (Bremner et al., 2002). Therefore, 
atrophy of the hippocampus may explain the memory defects experienced with 
depression (Bremner et al., 2000), and the reduction in cortical volume of 
prefrontal cortices reveal possible mechanism for the “deficits in emotion, mood, 
and social regulation” in major depression (Bremner et al., 2002).  
 In addition to examining the brain structural differences and molecular 
changes in MDD, studies have also looked at functional differences, such as 
cerebral blood flow, cerebral glucose metabolism and connectivity. Studies of 
cerebral blood flow in MDD have found conflicting results depending on the brain 
region under investigation (Segawa et al., 2006). The most consistent finding to 
date is decreased perfusion and metabolism in the frontal region of the brain and 
increased blood flow in the ACC, in depressed patients compared to healthy 
controls after corrections for brain volume (Milo et al., 2001; Bench et al., 1992; 
Awata et al., 2002; Drevets et al., 2008). The ACC has been shown to modulate 
emotional behavior, along with the medial prefrontal cortex, these brain regions 
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have been identified as key structures for MDD (Horn et al., 2010; Drevets et al., 
2008). Changes in blood flow or metabolism level reflect regional or global neural 
function, and it is influenced by changes in synaptic transmission that can be 
associated with alterations in neurotransmitter concentration or receptor activity 
or with changes in synaptic connection resulting from regional brain volume 
changes (Drevets, 1998). It is important to note that changes in blood flow or 
metabolic activity can reflect either the “physiological correlates of depressive 
emotions and thoughts or pathophysiological changes that predispose subjects 
to or result from affective disease” (Drevets, 1998).  
Functional connectivity and resting state magnetic resonance imaging 
(MRI) studies in MDD have found hyperconnectivity in regions that are part of the 
default mode network (DMN), especially in the subgenual ACC (sgACC) 
(Greicius et al., 2007; Berman et al., 2010; Zhu et al., 2012). The DMN is 
important  
“in self- referential activities, being described as low frequency 
toggling between a task independent, self-referential, and 
introspective state and an extrospective state the ensures the 
individual is alert and attentive to unexpected or novel 
environmental events” (Zhu et al., 2012).  
 
More specifically, the anterior region of the network is associated with self-
referential processing, such as the sgACC, while the posterior region is 
associated with memory retrieval (Greicius et al., 2007). Greicius et al. 
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hypothesized that the emotional and constant self reflective tendencies seen in 
depressed patients is possibly related to an increase in functional connectivity in 
the frontal parts of the DMN, versus a reduction in functional connectivity of the 
posterior part of the network might be more involved in cognition and memory 
impairments in these patients (Greicius et al., 2007). As such, studies have found 
hyperactivity in the ventral medial PFC and hypoactivity in the dorsolateral PFC, 
which both shows trends towards normalization during remission (Koenig et al., 
2009).  
 Although research efforts have tackled the biological underpinnings of 
MDD from many perspectives, the complexity of the illness prevents a single 
explanation for its etiology. The reduced brain volume, changes in 
glutamate/GABA levels, and hyperconnectivity in several brain regions 
consistently found in patients with depression suggests that secondary to a wide 
spread change in brain physiology and biochemistry, the direction of the change 
may be dependent on individual brain regions that have specific cognitive or 
emotional function. Thus, to develop more effective treatments for this pervasive 
and disruptive illness, a focus on treatments that target a wide range of neural 
circuits and are also capable of inducing circuit specific changes may yield a 
more immediate therapeutic effect.  
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Neuroplasticity Hypotheses for the Mechanism of ECT 
 To date, a unifying mechanism for ECT in MDD is still elusive. The 
complex and wide spread dysfunctions caused by the illness suggests that the 
mechanism is unlikely to be of a single source. However, converging evidence 
from several fields of research suggest that ECT’s overall effect is to correct 
dysfunctional activity through neuroplasticity induction.   
 Interestingly, albeit that ECT exerts its therapeutic effect through the 
induction of grand mal seizures (Fink, 2014b), it actually has anticonvulsive 
properties that are strongly correlated to clinical response (Sackheim, 1999). 
Patients on average experience a 40-100% increase in their seizure threshold 
over a course of treatment, consequently the patient becomes increasingly more 
resistant to seizure initiation (Sackeim et al., 1987; Coffey et al., 1995). This 
increased resistance suggests that ECT alters brain physiology, and the effect is 
likely wide spread (Sackeim et al., 1994).  However, the alteration is not 
permanent, with many patients reverting back to baseline seizure threshold after 
discontinuation of ECT (Sackheim, 1999). It has also been demonstrated that 
bilateral ECT results in much greater increase in seizure threshold than RUL 
ECT (Sackheim et al., 1987). Therefore, a significant increase in seizure 
threshold is considered a marker of ECT efficacy, as only patients who 
responded to ECT show an increase in seizure threshold (Figure 1.) 
corresponding to the degree of their clinical response (Sackheim, 1999).  There 
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are also other clinical observations that support the anticonvulsive properties of 
ECT. Such as a decrease in seizure duration over a treatment course, reductions 
in regional cerebral blood flow and metabolism, increased slow wave activity in 
electroencephalogram (EEG), and enhanced transmission of inhibitory 
neurotransmitters and neuropeptides.  
 
Figure 1. Comparison of Seizure Threshold in Electroconvulsive Therapy Patients.  
Percent change in seizure threshold. Percent change in seizure threshold between 
responders and non-responders in two studies that compared seizure threshold between 
bilateral and unilateral electrode placement. Figure taken from Sackheim, 1999.   
 
 A neurotransmitter mechanism for this observed change in seizure 
threshold has been proposed. It has been found in animal studies that 
electroconvulsive shock (ECS) induced seizures through antagonism of the 
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GABA system (Bowery et al., 1976; Simmonds et al., 1980; Bradford et al., 
1995). GABA is the most abundant inhibitory neurotransmitter in the brain, and 
has been shown to be dysfunctional in mood disorders (Emrich et al., 1980). 
Binding of GABA to GABAA
 receptor enhances chloride ion channel opening, 
which hyperpolarized the neuronal membrane, causing an inhibitory effect 
(Brambilla et al., 2003). Drugs such as benzodiazepines, anticonvulsants and 
anesthetics bind to the GABAA receptor to mediate their effects. MDD is 
especially vulnerable to the effects of chronic stress (Luscher et al., 2011). It has 
been shown that chronic stress reduces the level and function of GABAA 
receptors in cortical and subcortical areas, and subsequent reduction in inhibitory 
transmission can greatly impair neurogenesis in the hippocampus (Luscher et al., 
2011). Additionally, clinical response to ECT in the patient population is 
correlated with an increase in GABA levels (Brambilla et al., 2003), which 
contributes to increases in seizure threshold. Interestingly, GABA has been 
shown to modulate the activity of dopaminergic, norepinephrine and serotonin 
systems of the central nervous system (Brambilla et al., 2003), which have all 
been implicated as dysfunctional systems in mood disorders. Unsurprisingly, 
ECT also influences the glutamatergic system, and has been shown to correct 
deficits in patients who responded to ECT (Michael et. al., 2003; Ende et al., 
2000; Pfleiderer et al., 2003). Thus the transmission of the major inhibitory and 
excitatory neurotransmitters, GABA and glutamate respectively, may provide a 
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possible platform to investigate the wide spread therapeutic mechanism and side 
effect profile of ECT.  
 Studies have also looked at the neural functional connectivity in patients 
with MDD compared to healthy controls. Functional connectivity represents areas 
of the brain that have coordinated activity during a goal-oriented task or at a 
resting state, these areas will show temporal correlations in blood oxygen level-
dependent (BOLD) signals during functional magnetic resonance imaging (fMRI)  
are thought to reflect the functional interaction between different populations of 
neurons (Greicius et al., 2003; Honey et al., 2009; Sheline et al., 2009). These 
correlations demonstrate intrinsic connectivity across broad brain regions and 
serve important functions such as vision, hearing, language and self-referential 
processing (Greicius et al., 2009, Sheline et al., 2009).  Evidence shows that 
structural connectivity of brain regions is interrelated to their functional 
connectivity, such that brain regions that are closer together show stronger 
interrelatedness (Honey et al., 2009). Therefore, functional connectivity also is 
reflective of the physical interactions between different neuron populations.  
Functional connectivity studies began by demonstrating increased neural 
activity during a cognitive task compared to baseline resting state. However, a 
network of brain regions known as the DMN demonstrates higher activity during 
rest than cognitive tasks, and has been referred to as regions of deactivation 
during goal-oriented tasks and is thus most active during resting states (Greicius 
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et al., 2003; 2009). The DMN is thought to be important in processing information 
about the world such as “remembering the past as well as planning for the future” 
(Sheline et al., 2009), and the decrease in its activity during goal-oriented task is 
to “attenuate the brain’s self-referential activity as a means of more effectively 
focusing on a task” (Sheline et al., 2009). The DMN includes areas of the dorsal 
and ventral medial prefrontal cortices, medial and lateral parietal cortex, and part 
of the medial and lateral temporal cortices (Sheline et al., 2009). Structural and 
functional studies in MDD have revealed abnormal brain circuits involved in 
emotional processing that fall within the anterior DMN (Sheline et al., 2009). 
Such changes can be, in part, due to the DMN’s susceptibility to maladaptive 
changes in neural networks due to factors such as early life stress, which can 
cause aberrant regulation of neuronal plasticity (Sheline et al., 2009).  
Research on the effects of ECT on functional connectivity shows 
normalization of aberrant functional connectivity in patients towards healthy 
controls (Abbott et al., 2013; Perrin et al., 2012). This suggests that ECT may 
mediate its therapeutic effects through restoring normal structural and functional 
connectivity in MDD. Similarly, given the importance of the glutamate/GABA 
system in coordinating excitatory and inhibitory activity across the brain and their 
implication in neuronal health and neurogenesis, the normalization of the two 
systems after ECT is likely correlated to the restoration of normal functional 
connectivity. Studies on the neuroendocrine and neurotrophic hypotheses of ECT 
further supports significant increases in serum BDNF post treatment, which 
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promotes neuronal growth, neuroplasticity (Bumb et al., 2015; Marano et al., 
2007), and also regulates GABA reuptake/inactivation (Brambilla et al., 2003). 
Studies have also shown increased cortical and subcortical volume after ECT 
(Jorgensen et al., 2016; Tendolkar et al., 2013; Ota et al., 2015; Sartorius et al., 
2015). Such changes have been attributed to ECT’s ability to induce 
neurogenesis in these structures (Tendolkar et al., 2013; Ota et al., 2015). Two 
regions of special interests are the amygdala and hippocampus, which have 
consistently been identified as centers of increased volume (Jorgensen et al., 
2016; Tendolkar et al., 2013). The amygdala has modulatory effects on the 
activity of the hippocampus, where in early depression an increase in amygdala 
volume is related to an increase in functional activity that influences 
hippocampus activity. This hyperactivation is normalized after remission to 
antidepressant treatment (Tendolkar et al., 2013). Together, the evidence further 
suggests that ECT induces beneficial plastic changes at the neuronal level that 
affect both structural and functional connectivity of the brain. 
In this thesis, we will review current literature on functional connectivity 
using fMRI and glutamate/GABA using magnetic resonance spectroscopy 
(MRS). We hypothesize that ECT mediates its therapeutic effect through 
correcting abnormal glutamate/GABA systems and restoring normal functional 
connectivity by remodeling brain structures involved in affective and cognitive 
processing.   
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PUBLISHED RESULTS 
 
Functional Connectivity 
Perrin et al., 2012 
In a 2012 study, Perrin et al. looked at the effect of ECT on functional 
connectivity of the whole brain in nine patients (Perrin et al., 2012). The patients 
were given brief-pulse, bilateral ECT treatments twice a week, the mean number 
of treatments administered was 8.3. Clinical measures such as the Montgomery 
Asberg Depression Rating scale (MADRS) were collected within 48 hours of the 
first treatment, after the 4th treatment and after the last treatment. The patients 
were scanned before and after ECT treatments using a 3 Tesla MRI scanner. 
The amount of time before and after each ECT session was unclear. During the 
scans, each patient was instructed to perform a virtual ball passing cognitive task 
to help focus attention. The authors suggested that a simple cognitive task will 
reduce within group variance as resting state fMRI usually causes greater inter-
subject variance because patients may be thinking about different things and are 
also prone to falling asleep (Perrin et al., 2012).  
Instead of using predetermined candidate seed regions, they used 
weighted global connectivity (WGC) to compare before and after treatment 
effects. This approach allows quantification of the degree of connection between 
each voxel to all other voxels in the brain. They found a significant decrease in 
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average global connectivity in a cluster in the left dorsolateral prefrontal cortex 
(DLPFC), meaning that the connectivity of each voxel within the cluster to the 
voxels of the rest of the brain is significantly reduced (Perrin et al., 2012). This 
cluster was then used as a seed region to find other regions of the brain that it is 
functionally connected to. Results (Figure 2.) of this additional analysis showed 
that ECT significantly reduced connectivity between medial cortical structures, 
bilateral DLPFC, and left supermarginal gyrus, angular gyrus and somatosensory 
association cortex. Patients in this study showed significant reduction in 
depression symptoms after ECT.   
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Figure 2. Functional Connectivity of Dorsolateral Prefrontal Cortex Seed Region. 
Orange regions denote areas of significant connectivity with DLPFC before ECT 
treatment in patients with depression. Blue regions denote areas of significant functional 
connectivity with DLPFC that persisted after ECT treatments. Z value refers to distance 
in millimeters from the midline of Montreal Neurological Institute stereotaxic space. 
Figure modified from Perrin et al., 2012.  
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Beall et al., 2012 
Another 2012 study, by Beall et al., investigated the changes in activation 
and connectivity during task based and resting state fMRI before and after ECT 
treatments in ECT naïve patients (Beall et al., 2012). Six patients with MDD or 
bipolar affective disorder were enrolled. Patients received an average of 9 
bilateral ECT treatments and were scanned 1 week before first ECT treatment 
and 1 to 3 weeks after last ECT treatment using a 3 Tesla MRI scanner with a 12 
channel head coil. At each scan, working memory, affective pictures and resting 
connectivity scans were acquired. For working memory, a 2 back spatial working 
memory task was used. Patients were presented with four empty boxes on a 
display monitor that contains a white ball in one of the boxes. They were then 
instructed to remember the locations of the white ball for 2 presentations. For 
affective pictures, patients were shown a series of neutral and unpleasant 
pictures, and were asked to indicate when a new picture was presented (Beall et 
al., 2012).  
 ECT effect on activation was assessed by linear correlation of activation in 
regions of interests (ROI) to changes in Hamilton Rating Scale for Depression 
(HAM-D) . Mean activation values were compared in DLPFC, superior parietal 
lobe, superior cerebellum, posterior cingulate cortex and premotor cortex ROIs 
for the working memory task. Mean activation were compared in the right 
DLPFC, anterior cingulate cortex, medial prefrontal cortex, orbitofrontal cortex 
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and inferior parietal lobe ROIs for the affective task. Mean activation changes 
before and after ECT in individual ROIs were then correlated to HAM-D score 
changes (Beall et al., 2012). It is important to note that regions of deactivation 
and activation are all considered “activation” to examine all significant changes in 
blood flow in both directions. Resting state functional connectivity (rsFC) was 
analyzed between ROIs. The effect of ECT on rsFC is also tested by linear 
correlation between changes in connectivity and HAM-D scores before and after 
ECT.  
 In the task-related activation analysis, Beall et al. found a reduction in the 
absolute level of activation or deactivation in most regions during working 
memory and affective picture tasks after ECT, with exception of increased 
activation (or deactivation) in the cerebellum and posterior cingulate cortex 
during working memory task. The greatest reduction in deactivation was in the 
orbitofrontal cortex in the affective task. Mean activation in orbitofrontal cortex 
was found to be significantly correlated to changes in HAM-D scores in patients 
(Beall et al., 2012).  
rsFC analysis showed a decrease in the connectivity of left anterior 
cingulate cortex and orbitofrontal cortex and an increase in the connectivity 
between right ACC and orbitofrontal cortex, ACC and caudate after treatment. 
The most significant increase in connectivity found in the study is between the 
ACC, the right DLPFC and posterior cingulate cortex. No significant correlation 
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between connectivity change and HAM-D change survived after corrections for 
multiple comparisons (Beall et al., 2012).  
Wei et al., 2014 
 An interesting study examining interhemispheric functional coordination 
modulation by ECT was done by Wei et al. in 2014. The study included 11 
patients with depression and 15 group-matched healthy controls. The patients 
underwent a mean of 7 bifrontal ECT treatments, while the controls did not 
receive any. HAM-D scores were collected 12-24 hours before and 24-72 hours 
after ECT from patients. Both patients and healthy controls underwent resting 
state (rs) fMRI scans. Patients were scanned twice, 12-24 hours before and 24-
72 hours after ECT, while healthy controls were scanned once. Scanned were 
done with a 3 Tesla scanner (Wei et al., 2014).  
 The study used voxel mirrored homotrophic connectivity (VMHC) method 
to assess interhemispheric coordination effects of ECT. VMHC “indexes the 
resting-state functional connectivity between each voxel in one hemisphere and 
its mirrored counterpart in the opposite hemisphere” (Wei et al., 2014). To 
perform VMHC computation, a mean image of normalized gray matter images of 
all subjects was created and averaged to create a left-right symmetrical template. 
Then individual gray matter images were registered to the symmetrical template.  
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Comparing pre-ECT to post-ECT scans in patients, they found significantly 
increased VMHC in superior frontal gyri, middle frontal gyri, and angular gyri 
(Table 1) (Wei et al., 2014). In comparison between healthy controls and pre-
ECT patients, significantly lower VMHC was reported in the middle frontal gyri 
and angular gyri. Comparing healthy controls to post-ECT patients, significantly 
higher VMHC was reported in superior frontal gyri and middle frontal gyri (Figure 
3). No significant correlation was found between reductions in HAM-D score and 
VMHC changes in the superior frontal gyri, middle frontal gyri, or angular gyri 
when comparing pre-ECT and post-ECT conditions. There was also no 
significant correlation between the number of ECT treatments and VMHC 
changes in the superior frontal gyri, middle frontal gyri, or angular gyri. 
Table 2. Voxel Mirrored Homotrophic Connectivity Changes Following 
Electroconvulsive Therapy. Three brain regions showed significant homotrophic 
connectivity changes (VMHC) changes after electroconvulsive therapy (ECT) during 
resting state (rs) functional connectivity scan. MNI coordinates refer to Montreal 
Neurologic Institute coordinates. MNI coordinates and t-scores are both for the peak 
voxel. Table modified from Wei et al., 2014.  
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Figure 3.  Comparison of Voxel Mirrored Homotrophic Connectivity in Brain 
Regions.  Graph demonstrates a significant increase in voxel mirrored homotrophic 
connectivity (VMHC) between healthy controls (HC) and patients before 
electroconvulsive therapy (ECT) (Pre) and after ECT (Post).  “*” Denotes significant 
difference between comparison group and healthy control. There were two clusters 
(clusters A and B) within the middle frontal gyri that were found to be significantly 
increased in VMHC after ECT in the patient group. (a) Compared to HC, patients after 
ECT showed significantly higher VMHC in the superior frontal gyri. (b) Compared to HC, 
patients before ECT showed significantly lower VMHC in the middle frontal gyri in cluster 
A. (c) Compared to HC, patients after ECT showed significantly higher VMHC in the 
middle frontal gyri in cluster B. (d) Compared to HC, patients before ECT showed 
significantly lower VMHC in the angular gyri. Figure modified from Wei et al., 2014.  
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Abbott et al., 2013 
 Abbott et al. (2013) examined the rsFC in four regions affected in MDD in 
a 2013 study. They looked at subcallosal cingulate gyrus (SCC), DMN, DLPFC 
and dorsomedial prefrontal cortex (DMPFC) in patients with MDD compared to 
age and gender matched healthy controls (Abbott et al., 2013). A total of 12 
patients and 12 healthy controls were included in the study. Ten patients 
received brief pulse RUL ECT and 2 patients received brief pulse bitemporal 
ECT, on average the patients received 11 treatments. Resting state scans were 
acquired with a 3 Tesla scanner over a minimum of 5 minutes. Baseline clinical 
assessment (24 item Hamilton Depression Rating Scale (HDRS-24)) and resting 
state scan were done 1 to 2 days before the first ECT treatment. Post-ECT 
assessments and resting state scan were done at least 5 days after their last 
treatment.  
 The group performed an independent component analysis (ICA) instead of 
a seed based analysis (Abbot et al., 2013). Unlike seed based analysis, where 
one predetermines an area of interest, ICA identifies functionally connected brain 
regions by looking for temporal coherence in hemodynamic changes of all brain 
regions (Abbott et al., 2013). Therefore, ICA is thought to be less arbitrary than 
seed based analysis and consider all information between voxels, therefore 
increasing sensitivity in detecting between group differences.  
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Clinical assessment analysis found that responders to ECT treatment 
showed a significant reduction in HRDS-24 scores compared to non-responders 
(Figure 4) (Abbott et al., 2013). Nine patients were considered remitters. In 
functional connectivity analysis, components of interests were further divided into 
anterior default mode (a_DM), SCC, DMPFC, posterior default mode (p_DM), 
and right/left DLPFC (r_DLPFC, l_DLPFC). Primary analysis of longitudinal 
changes in functional connectivity found that correlation between p_DM and 
DMPFC changed from negative to positive after ECT treatment. Connectivity 
correlation between p_DM and l_DLPFC also changed from negative to weak 
positive after ECT. Secondary analysis compared pre-ECT depressed patients 
with healthy controls in the functional connectivity in significant network pairs 
identified via primary analysis. Compare to healthy controls, patients had 
significantly lower connectivity between p_DM and DMPFC, and pDMN and 
l_DLPFC. Last but not least, they also found that connectivity increased 
significantly in p_DM and l_DLPFC after ECT in remitters but not non-remitters 
(Abbott et al., 2013).  
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Figure 4. Functional Connectivity Comparison Following Electroconvulsive 
Therapy. Shown is connectivity between patient (pre/post-electroconvulsive therapy 
(ECT)) and healthy controls. Y axis represents direction and magnitude of functional 
connectivity correlation. Red solid lines – average of healthy control connectivity 
correlations of that region. Dashed red lines – standard errors of healthy control 
connectivity. DMPFC- dorsomedial prefrontal cortex. P_DM – posterior default mode 
network. DLPFC – dorsolateral prefrontal cortex. (A). Pre-ECT patients had significantly 
lower connectivity between DMPFC and p_DM compared to healthy controls. 
Connectivity shows a trend of normalization towards healthy control after ECT. (B). Pre-
ECT patients show significantly lower connectivity between DLPFC and p_DM compared 
to healthy controls. Connectivity shows a trend of normalization towards healthy control 
after ECT. Figure adapted from Abbott et al., 2013.  
 
Liu et al., 2015 
 In their 2015 study, Liu et al. hypothesized that ECT resets “regional 
activity and neuroplasticity of distant connectivity in the subgenual anterior 
cingulate cortex (sgACC)” in patients with major depression (Liu et al., 2015). 
They measured changes in both spontaneous whole brain activity and functional 
connectivity before and after ECT treatments. The study included 23 patients 
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who underwent brief pulse bitemporal ECT. All patients received at least 8 ECT 
treatments and at most 12 treatments. They were scanned 1 day before the first 
session of ECT and were scanned again more than 24 hours after 8 ECT 
treatments. All scans were performed using a 3T MRI scanner; resting scans 
were acquired by instructing patients to relax with their eyes closed and staying 
awake. HAM-D questionnaire was given 1 day before ECT and the day after 8 
ECT treatments as clinical assessment. Two types of analyses were performed, 
amplitude of low frequency fluctuation analyses (ALFF) and functional 
connectivity. Functional connectivity analyzed from a seed based approach in the 
sgACC (Liu et al., 2015).  
 The DMN showed the greatest ALFF value in both pre-ECT and post-ECT 
scans (Liu et al., 2015). The left sgACC, left hippocampus (HIP), bilateral 
orbitofrontal cortex (OFC), right pregenual (pg) ACC, and right pre-central gyrus 
showed a significant increase in ALFF after ECT. Significant decreases in ALFF 
was also observed in the middle posterior dorsal (pd) ACC (Figure 5). Functional 
connectivity between seed region sgACC and all other voxels in the brain 
showed an increase in connectivity between left sgACC and ipsilateral 
parahippocampal gyrus, pgACC, contralateral middle temporal pole (MTP), and 
OFC (Figure 6). The clinical assessment showed a negative correlation between 
increased activity in the left sgACC and reduced HAM-D scores. There was also 
a negative correlation between increased functional connectivity in the sgACC 
and MTP and reduced HAM-D scores. 
 34 
 
 
Figure 5. Amplitude of Low frequency Fluctuation (ALFF) Analysis. L. sgACC – left 
subgenual anterior cingulate cortex (ACC). R. pgACC- right pregenual ACC. L HIP – left 
hippocampus. L.OFC- left orbitofrontal cortex. R. OFC – right orbitofrontal cortex. R. 
PreCG – right precentral gyrus. pdACC- posterior dorsal ACC. Figure taken from Liu et 
al., 2015.  
 
Figure 6. Functional Connectivity with Subgenual Anterior Cingulate Cortex. L. 
Parahip– left parahippocampus. L. pgACC – left pregenual anterior cingulate cortex 
(ACC). L. SFGOrb – Left superior orbtiofrontal cortex. R. IFGOrb – Right inferior 
orbitofrontal cortex. MFGOrb – Middle orbitofrontal cortex. MTGP – Middle temporal 
gyrus, pole. Figure taken from Liu et al., 2015. 
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Cano et al., 2015 
Cano et al. were interested in the effect of ECT on limbic and prefrontal 
connectivity in treatment resistant MDD (Cano et al., 2015). In their 2015 study, 
they looked at how ECT affects sgACC and DLPFC to amygdala functional 
connectivity at different points during a course of ECT. Specifically, they looked 
at before ECT, after one treatment, after nine treatments and 15 days after the 
last ECT treatment. They tested if the connectivity from amygdala to sgACC and 
amygdala to DLPFC would change sequentially over a course of ECT treatment. 
13 patients with treatment resistant MDD and 10 age and gender matched 
healthy controls were included in the study. All patients received bifrontotemporal 
ECT and were scanned a total of four times with a 3 Tesla MRI scanner. On 
average the patients received 12 ECT sessions. They were scanned 24-48 hours 
before the first ECT (fMRI 1), 24-48 hours after the first ECT (fMRI 2), 24-48 
hours after the ninth ECT (fMRI3) and 15 days after the last ECT (fMRI 4). 
Healthy controls were scanned twice, 5 weeks apart. Resting state functional 
connectivity (FC) scans were acquired with an 8 channel head coil. ECT’s effect 
on FC was assessed by seed based analysis. Four ROIs were selected, left and 
right laterobasal amygdala (lbA) and left and right superficial-centromedial nuclei 
of the amygdala (sf/cmA). Left and right anatomical masks of FC target regions 
were generated for sgACC and DLPFC. Comparison time points were from 
fMRI1 to fMRI2, from fMRI1 to fMRI3 and from fMRI1 to fMRI4. Additionally, the 
Hamilton Rating Scale for Depression (HSRD) was used to assess clinical 
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response to ECT. The HSRD score was used in a PATH analysis to test the 
association between clinical response and FC changes. PATH analysis allows 
testing of the effect of both indirect and direct variables on an outcome of 
interest. In this study, they tested the direct and indirect effects of ECT on 
functional connectivity changes during early and late treatments. Additionally, 
they also tested the direct and indirect effects of functional connectivity changes 
on clinical outcome (Cano et al., 2015).  
  FC analysis (Figure 7) found that patients had a decreased FC between 
right sf/cmA and left sgACC after fMRI2 and remained significant after fMRI3. An 
increased FC between right sf/cmA and right DLPFC was also observed after 
fMRI3 (Cano et al., 2015). Healthy controls showed no significant difference in 
FC between their two scans. PATH analysis yielded three direct findings (Figure 
8). Firstly, the decrease in right sf/cmA to left sgACC FC after fMRI2 was directly 
associated with the decrease in sf/cmA to left sgACC FC after fMRI3. Secondly, 
the decrease in sf/cmA to left sgACC FC after fMRI3 was directly associated with 
the increased FC in right sf/cmA to right DLPFC after fMRI3. Lastly, increased 
FC in right sf/cmA to right DLPFC after fMRI3 was directly correlated to clinical 
improvement after fMRI4. Several indirect findings were also reported (Figure 8). 
Decreased FC in right sf/cmA to left sgACC after fMRI2 was indirectly associated 
with increased FC in right sf/cmA to right DLPFC after fMRI3 and clinical 
improvement. Decreased FC in right sf/cmA to left sgACC after fMRI 3 was also 
indirectly associated to clinical improvement (Cano et al., 2015).  
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Figure 7. Functional Connectivity Changes in Patients. Functional connectivity was 
evaluated over 9 electroconvulsive therapy (ECT) sessions. fMRI2 – fMRI1: functional 
magnetic resonance imaging (fMRI) FC differences between before first ECT treatment 
(fMRI1) and after the first ECT treatment (fMRI2). fMRI3 – fMRI1; FC differences 
between fMRI scan after the ninth ECT treatment (fMRI3) and before the first ECT 
treatment (fMRI1).  Color bars on the left indicate t value. (A). FC between right 
superficial-centromedial amygdala (sf/cmA) and left subgenual anterior cingulate cortex 
(sgACC) decreased (both in red). (B). FC between right sf/cmA and left sgACC 
decreased (red region). (C). FC between right sf/cmA and right dorsolateral prefrontal 
cortex (DLPFC) increased (blue region). Figure modified from Cano et al., 2015.  
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Figure 8. Effects of Functional Connectivity Change on Electroconvulsive Therapy 
Clinical Outcome. Decreased FC in right superficial - centromedial amygdala (rsf/cmA) 
and left subgenaual anterior cingulate cortex (LsgACC) after functional magnetic 
resonance imaging after first ECT (fMRI2) directly correlated to decreased FC in rsf/cmA 
and LsgACC after fMRI after 9th ECT treatment (fMRI3). Decreased FC in rsf/cmA and 
LsgACC after fMRI3 is directly correlated to increased FC in rsf/cmA and right 
dorsolateral prefrontal cortex (rDLPFC) after fMRI3. Increased FC in rsf/cmA and right 
dorsolateral prefrontal cortex (rDLPFC) after fMRI3 directly correlated to clinical 
improvement at fMRI 15 days post last ECT treatment (fMRI4). Decreased FC in rsf/cmA 
and LsgACC after fMRI2 indirectly correlated to increased FC in rsf/cmA and rDLPFC 
after fMRI3. Decreased FC in rsf/cmA and LsgACC after fMRI3 indirectly correlated to 
clinical improvement at fMRI4. Figure modified from Cano et al., 2015.  
Magnetic resonance spectroscopy: Glutamate and GABA 
Michael et al., 2003 
 Michael et al. conducted a study in 2003 to look at whether ECT 
normalized glutamate disruptions in the left DLPFC in patients with severe 
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treatment resistant unipolar depression (Michael et al., 2003). Twelve patients 
and 12 age and gender matched controlled were included in the study. The 
patients were treated with brief pulse ECT and they received a mean of 10 ECT 
treatments in total. Magnetic resonance spectroscopy (MRS) measurements in 
patients were taken 2 days before the first ECT treatment and at least 30 hours 
after the last ECT treatment (1-3 days). Healthy controls were scanned once. 
Measurements were done at 1.5 Tesla field strength and single voxel stimulated 
echo acquisition mode (STEAM) spectroscopy was used. Post processing of 
MRS signals was done with linear combination (LC) model. Glutamate, GABA 
and glutamine concentrations were measured together as “Glx” due to the 
difficulty of separating these overlapping resonances at the given field strength 
(Table 2, Figure 9). 
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Table 2. Metabolite levels in Left Dorsolateral Prefrontal Cortex. Metabolite levels 
reported for controls, pre-electroconvulsive (pre-ECT) and post-ECT patients with major 
depression groups. Glx- glutamine/glutamate/GABA. CSF – cerebrospinal fluid. NAA – 
N-acetylaspartate – NAA. Cho – Choline. Cr- Creatine. ECT non-response patients were 
those who did not respond to 10 consecutive treatments. * Significantly different from 
controls. **Significantly different from pre-ECT measurements. Table modified from 
Michael et al., 2003.  
      
 
Figure 9. Combined Glutamine/Glutamate/GABA Level Following 
Electroconvulsive Therapy. Responders are patients who responded to 10 ECT 
treatments. Their Glx was significantly increased after treatment. Non-responders are 
patients who did not respond to 10 ECT treatments and showed low or good response 
after additional treatments. Glx increased in patients who showed response to additional 
treatments. Figure modified from Michael et al., 2003.  
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Pfleiderer et al., 2003 
A study by Pfleiderer et al. in 2003 assessed Glx changes in the left ACC 
in patients with MDD before and after ECT (Table 3) (Pfleiderer et al., 2003). A 
total of seventeen patients and seventeen age and gender matched controls 
were included in the study. MRS measurements were taken before ECT and 24-
48 hours after the last ECT in the patient group. Healthy controls underwent two 
MRS measurements, 5 months apart to assess the reproducibility of the Glx 
measurements. The patients received on average 13 ECT brief pulse treatments 
in either unilateral or bilateral administration. MRS measurements were done 
with single voxel STEAM spectroscopy at 1.5 Tesla field strength. Analyses were 
done with LC model program package. Similar to Michaels et al., Pfleiderer et al. 
also examined Glx concentration due to the difficulty of separating the 
overlapping resonances of glutamate, glutamine and GABA at 1.5 Tesla. The 
assumption is made as glutamate concentration is much higher than GABA or 
glutamine levels in each 1 mmol/kg of brain tissue (Figure 10) (Pfleiderer et al., 
2003). 
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Table 3. Metabolite Changes in Anterior Cingulate Cortex Following 
Electroconvulsive Therapy. Voxel composition and metabolite levels (in institutional 
units (IU)) in the anterior cingulate cortex in patients with depression before and after 
electroconvulsive therapy (ECT) and healthy controls. a. Significantly different from 
controls. b. Significantly different from pre-ECT measurements. Glx-
glutamate/glutamine/GABA. NAA – N-acetylaspartate. Cho – choline. Cr – creatine. CSF 
– cerebral spinal fluid. Only Glx levels significantly changed after ECT responders. 
Significant reduction in Glx is seen in pre-ECT patients compared to healthy controls. 
Table modified from Pfleiderer et al., 2003.  
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Figure 10. Combined Glutamate/glutamine/GABA Level Following 
Electroconvulsive Therapy. * - Post-ECT. Patients before ECT showed significantly 
lower glutamate/glutamine/GABA (Glx) levels compared to controls. Patients who 
responded to ECT (response) showed a significantly increased Glx compared to pre-
ECT. Levels match that of healthy controls. Figure modified from Pfleiderer et al., 2003.  
 
Metabolite and voxel composition results are shown in Table 3. The pre-
ECT patient population showed a 67% reduction in Glx levels in the left ACC 
compared to healthy controls (Pfleidere et al., 2003). Patients also showed a 
significantly higher CSF fraction than healthy controls. Grey matter (GM) fraction 
was not reduced in patients compared to healthy controls. Patients who was 
responsive to ECT treatments (n=12) showed a significant increase in Glx in the 
 44 
 
left ACC compared to their baseline Glx level and was no longer statistically 
different from healthy controls (Figure 10). In contrast, non-responding patients 
did not show Glx increase. Nonresponders were given additional antidepressant 
treatments and was remeasured after response. They showed significantly 
increased Glx compared to baseline.  
Sanacora et al., 2003 
Sanacora et al. examined the effect of ECT on GABA levels in the 
occipital lobe in depressed patients (Sanacora et al., 2003). Eight subjects with 
major depression were included in this study. Patients were treated with either 
bilateral (n=7) or unilateral ECT (n=1). The mean number of treatments per 
patient was 8.5. MRS measurements were taken before ECT treatments and at 
least 1 day after the last ECT treatment. One patient’s post-ECT MRS 
measurement was made 46 days after the last ECT treatment. A 2.1 Tesla 
magnet bore with a Bruker Avance spectrometer was used for MRS 
measurements. GABA resonance editing was performed using a J editing pulse 
sequence.  
Figure 11 depicts the significantly increased GABA concentration in the 
occipital lobe after ECT (Sanacora et al., 2003). Seven out of eight subjects 
showed increased cortical GABA concentrations after ECT treatments, four 
patients had increases of over 85%. Seven out of eight patients also showed 
significantly decreased seizure duration over the course of ECT treatment. 
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Although two patients showed complete remission and five patients showed 
partial response, there was no significant correlation between clinical response 
and change in cortical GABA concentrations.  
 
Figure 11. Gamma Aminobutyric Acid Level Following Electroconvulsive Therapy.  
GABA levels in the occipital cortex of patients before and after they received 
electroconvulsive therapy (ECT). Each line indicates a distinct patient. Figure taken from 
Sanacora et al., 2003. 
Merkl et al., 2011 
 The 2011 MRS study by Merkl et al. looked at the absolute levels of 
different metabolites between patients with depression and healthy controls. 
They hypothesized that patients will have lower levels of glutamate and NAA at 
baseline compared to healthy controls and these levels will normalize after 
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remission (Merkl et al., 2011). A total of 25 patients and 27 age and gender 
matched healthy controls were included in the study. Patients were treated with 
right unilateral ultrabrief pulse ECT, with exception for two patients, who received 
bilateral and brief pulse ECT. All patients received at least 9 ECT treatments. For 
patients who did not show response to treatment, ECT was continued for them 
until clinical response is observed (continuation phase). The investigators defined 
response to treatment as a 50% reduction in the Hamilton Depression Rating 
Scale (HDRS). There were three time points where clinical and/or MRS 
measurements were made, at baseline (T0), after 9 ECT treatments (T_acute), 
and after the last continuation ECT treatment (T_1). MRS measurements were 
done at T_0 and T_acute in patients. Healthy controls were scanned once. All 
MRS measurements were made with a 3 Tesla scanner and spectroscopy was 
recorded from the left DLPFC and ACC (Merkl et al., 2011).  
 For the patient population, 32% showed clinical response after 9 ECT 
treatments and 68% showed response after additional continuation treatments 
(Merkl et al., 2011). Comparing patients at baseline to healthy control MRS data, 
no significant differences in metabolite levels were found in the left DLPFC 
(Table 5). However, patients showed a decrease in NAA and glutamate levels in 
the ACC compared to healthy controls (Table 4). Upon closer examination, 
reduction of NAA and glutamate levels in the ACC was only significant between 
ECT responder and healthy controls. After ECT, only responder group showed a 
significant decrease in NAA in the left DLPFC and an increase in NAA in the 
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ACC. Through a correlation analysis, they found that high baseline glutamate 
level was correlated to a greater reduction in HDRS score at time T_1, which 
implied that higher glutamate level predicted better clinical response to ECT. 
Lastly, glutamate levels were found to correlate positively with NAA levels in ACC 
and DLPFC at baseline in all subjects (patients and healthy controls) (Figure 12).  
 
Table 4. Metabolite Levels in Anterior Cingulate Cortex. tCho – total choline. tCr – total creatine. NAA – N-acetylaspartate, 
Glu – glutamate. ECT – electroconvulsive therapy. MDD – major depression. HC- healthy control. T0 – baseline. T_acute – after 
9 ECT treatments. a & b = P < 0.05. Table modified from Merkl et al., 2011.  
 
 
Table 5. Metabolite Levels in Left Dorsolateral Prefrontal Cortex. tCho – total choline. tCr – total creatine. NAA – N-
acetylaspartate, Glu – glutamate. ECT – electroconvulsive therapy. MDD – major depression. HC- healthy control. T0 – 
baseline. T_acute – after 9 ECT treatments. Table modified from Merkl et al., 2011. 
 
4
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Figure 12. Correlation of Hamilton Depression Rating Scale Score and Glutamate 
Level. Glutamate level reported from the anterior cingulate cortex of patients. Higher 
glutamate levels at baseline predicted a greater reduction in the seventeen itemed 
Hamilton Depression Rating Scale Score (HDRS -17) score after electroconvulsive 
therapy (ECT). Figure taken from Merkl et al., 2011.  
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DISCUSSION  
  
Major depressive disorder (MDD) is characterized by ongoing feelings of 
guilt, sadness and worthlessness, as well of memory, cognition, sleep and 
motivation impairment and even vulnerability to physical pain (Horn et al., 2010; 
Hecht et al., 2010). It is a multidimensional illness that affects “discrete, but 
functionally integrated, [brain] pathways” (Mayberg et al., 2003). Understanding 
the underlying brain dysfunction that gives rise to this complex illness has been 
challenging, and by extension the search for appropriate treatments. Currently, 
only about 50% of patients who suffer from major depression show a sustained 
response to one form of pharmacological antidepressant (Husain et al., 2002). As 
such, patients who fail to respond to “at least two adequate trials of medications 
from different classes in the current episode” (Rush et al., 2003) are considered 
treatment resistant. These patients may suffer from an underlying metabolic 
disorder that prevents pharmacological interventions from being properly dosed 
or that they show a much more delayed response to conventional antidepressant 
medications and thus failed to show response within the expected time frame 
(Rush et al., 2003). These patients make up the primary population that receives 
electroconvulsive therapy (ECT) for major depression. Remarkably, ECT shows 
a 75% remission rate (Husain et al., 2004; Hermann et al., 1995; Weiner et al., 
2001) in this patient population and is considered the “gold standard” treatment 
for major depression (Abbott et al., 2013). Although the exact mechanism of its 
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function is unknown, it is well accepted that the induced grand-mal seizure 
confers its therapeutic effect (Fink, 2008). The seizure likely has broad effect that 
somehow corrects the underlying dysfunction in brain circuitry. Here, we 
specifically examined studies of functional connectivity and metabolite changes.  
 Perrin et al. found that after bilateral ECT treatments, patients with major 
depression showed an overall reduction of functional connectivity (FC) from the 
left dorsolateral prefrontal cortex (DLPFC) to other cortical and limbic structures. 
Hyperconnectivity in this area has been found in major depression, and therefore 
ECT may attenuate the pathological connectivity.  In addition, it is interesting that 
their finding is localized to the left side of the brain as interhemispheric activity 
asymmetry is well documented in mood disorder (Hecht et al., 2010). In 
depression, it has been found that the right hemisphere is hyperactive, while the 
left hemisphere is hypoactive. This imbalance is associated with a tendency to 
focus attention inwards and towards fearful and sad stimuli, causing a deep 
sense of negativity (Hecht et al., 2010). The interesting laterality of ECT’s 
therapeutic effect found in Perrin et al.’s study is supported by Wei et al.’s and 
Beall et al.’s studies. Wei et al. found that correlated activity between the superior 
frontal gyri, middle frontal gyri and angular gyri were significantly increased after 
ECT. Increased coordination between the middle frontal gyri, an area known for 
emotion regulation (Wei et al., 2014), was correlated to reduction of depressive 
symptoms. Additionally, Wei et al. found an increased coordination in the angular 
gyrus after ECT, a key component to the default mode network (DMN), is in 
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agreement to findings of decreased metabolism, blood flow and coherence 
based regional homogeneity in this area in depressed patients. Beall et al. found 
that after ECT, hyperdeactivation of the orbitofrontal cortex to negative emotional 
stimuli was decreased in patients, and this decrease was also associated with 
improvement in depressive symptoms (Beall et al., 2012). These studies suggest 
that ECT’s therapeutic effect is in rebalancing the functional asymmetry between 
the hemispheres and normalizing hyperactive areas.  
 Liu et al. found increased regional activity in the subgenual ACC (sgACC) 
in treatment naïve patients after ECT and increased functional connectivity 
between the sgACC and left hippocampus that was correlated to reduction of 
depressive symptoms (Liu et al., 2015). Cano et al. found reduced connectivity 
between the amygdala and sgACC and increased connectivity between the 
amygdala and DLPFC in patient by sequential assessments over a course of 
ECT treatments (Cano et al., 2016). These results are consistent with 
abnormalities found in MDD. Patients show reduced activity in limbic areas, 
specifically reduced metabolism, grey matter volume in the sgACC (Liu et al., 
2015). The sgACC has been implicated as a major area of dysfunction in major 
depression and is responsible for mediating emotional and autonomic responses 
to external stimuli (Drevets et al., 1997). Therefore, increasing deficiency activity 
from the sgACC might be part of the therapeutic effects of ECT. Additionally, 
hyperconnectivity between the amygdala and sgACC and hypoconnectivity 
between limbic and PFC are also well documented in depression (Cano et al., 
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2016; Kupfer et al., 2012; Kaiser et al., 2015). Hypoconnectivity between limbic 
and PFC has been attributed to poor cognitive control seen in patients and their 
tendency to fall into negative ruminations (Kaiser et al., 2015). Last but not least, 
Abbott et al. found that ECT increased the functional connectivity between 
DLPFC and the default mode network (DMN) (Abbott et al., 2013). The DLPFC 
has been implicated in cognitive deficits observed in patients with depression 
(Abbott et al., 2013). The DMN includes multiple brain regions that are found to 
be involved in emotional processing, introspection and endocrine regulation, and 
hyperactivity of the DMN in depression can result in overactive rumination 
(Sheline et al., 2009). The increased connectivity between prefrontal areas and 
the DMN found in Cano et al. and  Abbott et al.’s studies points to ECT’s role in 
the restoration of top/down, executive control of the cognitive brain over these 
areas (Sanacora et al., 2012). However, it is more likely that ECT confirms the 
involvement of both cortical and subcortical structures in the depressed state and 
that normalization of the connectivity in these networks conveys the therapeutic 
mechanism of grand-mal seizures.  
 The changes in connectivity observed after ECT treatments suggest its 
role in neuroplasticity, such that it enhances weakened connections while 
attenuates hyperconnectivity. Although the correlation between functional and 
structural connectivity is not absolute, there is evidence that areas that are closer 
in proximity tend to show stronger correlated functional activity (Honey et al., 
2009). Therefore it is likely that a change in connectivity reflects a change in 
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physical connections between neurons. Given the anatomical basis for functional 
connectivity, it is interesting that ECT induces changes at the neuronal level. This 
effect can be seen in metabolite studies from magnetic resonance spectroscopy 
(MRS), specifically the major excitatory and inhibitory neurotransmitter systems, 
glutamate and GABA respectively. The use of MRS to examine total tissue 
metabolite levels in the brain bypasses the confounding factors usually 
associated with postmortem and plasma studies, and allows for direct 
measurement in living brain tissue (Sanacora et al., 2012).  
 It is well established that the brain undergoes significant synaptic 
remodeling during early years of development. Through learning, new 
experiences and emotional processing, areas of the brain is still continuously 
remodeled in adulthood (Sanacora et al., 2012). However, the brain is equally 
susceptible to changes induced by good experiences as it is by bad, such as 
stress. It has been shown that stress causes neuronal remodeling, atrophy and 
retraction, especially in early years of life (Sanacora et al., 2012). These negative 
neuroplastic changes likely contribute to the development of depressive 
disorders. In the glutamate system, it has been shown that induced stress, in the 
form of cortisone injection, causes excessive glutamate release in prefrontal 
cortices (Sanacora et al., 2012). This excessive release can cause toxic cellular 
neurodegeneration and contribute to grey matter volume loss observed in mood 
disorders (Krystal et al.,2001; Sanacroa et al., 2012; Brambilla et al., 2003). 
Additionally, drastic increases in glutamate release can also cause exhaustion of 
 55 
 
the glutamate system and lead to decrease in glutamate levels overtime (Michael 
et al., 2003). MRS studies of glutamate and depression consistently demonstrate 
reduced glutamate levels in the PFC and cingulate cortex in depressed patients 
(Sanacora et al., 2012). Concurrently, deficit in the GABA system has also been 
implicated in depression. Neuroplastic changes in the GABA transmission 
system have also been observed in stress models, where stress induced 
significant changes in the expression and function of GABA receptors in the adult 
brain (Luscher et al., 2011). In depression, decreased levels of GABA and 
downregulation of its receptors in areas of the cingulate cortex, PFC and 
hippocampus have been found (Luscher et al., 2011; Brambilla et al., 2003). 
Additionally, GABA has also been shown to modulate the activity of several 
major monoamine systems that have long been the targets of pharmacological 
antidepressant treatments, they are the dopamine, norepinehrine and serotonin 
systems (Luscher et al, 2011).  
 Therefore, we thought to examine MRS literature on ECT’s effect on brain 
metabolites in depression. We found that studies by Pfleiderer et al., Michael et 
al. and Merkl et al. all confirmed decreased levels of glutamate or glx 
(glutamate/glutamine/GABA) in patients in the ACC and DLPFC (Pfleiderer et al., 
2003; Merkl et al., 2011; Michael et al., 2003). Additionally, Michael et al. and 
Pfleiderer et al. found that glx levels increased after ECT treatments and that this 
increase was only found in responders (Pfleiderer et al., 2003; Michael et al., 
2003). These findings on the normalization of glutamate in only responders are 
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consistent with literature on mood disorder. Sanacora et al. found that GABA 
levels increased after ECT treatment in the occipital cortex (Sanacora et al., 
2003). This result is consistent with both literatures on mood disorder as well as 
the anticonvulsive properties of ECT. Such that increases in GABA levels are 
associated with increased seizure threshold during a course of ECT treatment 
(Sackheim et al., 1999; Sanacora et al., 2003). Together, these results suggest 
that ECT demonstrates neuromodulatory effects on both excitatory and inhibitory 
synaptic transmission. These effects are likely mediated through either the direct 
change in neurotransmitter release, which causes downstream synaptic 
remodeling or through the alteration of neuronal density in these systems.   
 Results from functional connectivity and brain metabolite studies in 
patients with major depression point to induced neuroplasticity as part of ECT’s 
therapeutic mechanism. Remodeling connectivity and mediating metabolite 
changes both will require modifications at the synaptic level. The wide spread 
changes seen in several different brain regions that have been implicated in 
depression further suggests that ECT’s effects are both highly specific and 
broad. However, these results must be taken with caution. Since the patient 
population studied in ECT is often severely depressed (Kellner et al., 2015), they 
are likely to have been prescribed many types of pharmacotherapy and are often 
kept on medications while receiving ECT treatments. The effects of these 
medications on connectivity and metabolite changes can be complex and 
extremely difficult to assess. The sample sizes of these studies are often very 
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small, studies of larger sample sizes are needed to extrapolate these findings to 
the general patient population. The ECT treatment parameters across studies are 
also difficult to standardize, as the therapeutic effect will vary from patient to 
patient. Last but not least, MRS data should be interpreted with extra caution as 
most studies examined here were performed at relatively low field strength. 
Therefore, many studies examined the combined peaks of glutamate, glutamine 
and GABA. Although the glx signal is mostly dominated by glutamate levels, the 
effect of other metabolites on this signal cannot be fully discounted. Additionally, 
MRS measures provide the total level of the metabolites in the brain, which 
includes both intracellular and intercellular concentrations, therefore, conclusions 
about metabolite levels involved in actual neurotransmission is difficult to make. 
Nonetheless, consistencies shown in these studies are promising and provide a 
good foundation for further magnetic resonance imaging studies of ECT’s 
therapeutic mechanism in depression.  
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CONCLUSION 
 
Depression is a multidimensional illness that affects multiple brain circuits. 
Early life stressors can cause maladaptive synaptic modeling that predisposes 
the formation of mood disorders. As such, treatments that target specific neural 
systems, such as monoamine based antidepressants, often produces very 
limited responses in patients and a high relapse rate. Development of 
antidepressant treatments that matches the widespread dysfunction seen in 
mood disorder is highly valuable. Electroconvulsive therapy has consistently 
demonstrated impressive efficacy among the most severely depressed patients 
and is known to produce widely distributed effects in the brain. However, this also 
makes assessing its therapeutic mechanism challenging. Magnetic resonance 
imaging studies assessing functional connectivity and brain metabolite levels 
have demonstrated that ECT likely produces neuroplastic changes to remodel 
aberrant connectivity and dysfunctional excitatory and inhibitory 
neurotransmission in cortical and limbic areas. Although these findings should be 
interpreted with caution, this field of research has provided an unprecedented 
opportunity to examine the living brain in great detail. Further studies with larger 
sample sizes and improved technical specifications will likely yield stronger 
results.  
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